Key Development American Industrial Partners has completed its acquisition of Avanos Medical in a transaction valued at approximately US$1.27 billion.... Read more
Category: Uncategorized
RIVERPOINT MEDICAL ACQUISITION MOVES NOVANTA DEEPER INTO THE SURGICAL CONSUMABLES MARKET
Key Development Novanta has completed its acquisition of Riverpoint Medical from Arlington Capital Partners, marking a significant expansion of its... Read more
VIETNAM POSITIONS TRADITIONAL MEDICINE AS A STRATEGIC PILLAR OF NATIONAL HEALTHCARE
Key Development Vietnam is developing a national traditional medicine strategy through 2030, with a longer term vision extending to 2045.... Read more
FINANCIAL STRESS IN EARLY ADULTHOOD MAY SHAPE BRAIN HEALTH DECADES LATER
Key Development Emerging evidence suggests that financial wellbeing should be viewed as a long-term determinant of brain health rather than... Read more
TP.HCM’S MULTIPLE SEASONAL OUTBREAK RISKS HIGHLIGHT THE NEED FOR STRONGER PREVENTIVE PUBLIC HEALTH SYSTEMS
Key Development As Ho Chi Minh City enters the peak of the rainy season, health authorities are strengthening surveillance and... Read more
ENVIRONMENTAL HEALTH RISKS ARE REDEFINING ESG ACCOUNTABILITY IN THE GLOBAL ENERGY SECTOR
Key Development Environmental health has become an increasingly important issue for industries operating in resource-rich regions. Recent allegations linking oil... Read more
MEDICAID FUNDING UNCERTAINTY IS RESHAPING THE FINANCIAL OUTLOOK FOR U.S. HOSPITAL OPERATORS
Key Development Universal Health Services (UHS) has revised its 2026 earnings outlook downward, citing growing uncertainty over the future of... Read more
PHILIP MORRIS’ US$1.2 BILLION U.S. EXPANSION REFLECTS THE ACCELERATING SHIFT TOWARD SMOKE-FREE NICOTINE PRODUCTS
Key Development Philip Morris International (PMI) has doubled its planned investment in its Aurora, Colorado manufacturing campus to approximately US$1.2... Read more
FDA SCRUTINY OF CAPRICOR’S CELL THERAPY UNDERSCORES A NEW BENCHMARK FOR RARE DISEASE INNOVATION
Key Development Capricor Therapeutics is facing a critical regulatory hurdle as U.S. FDA reviewers question whether the clinical evidence supporting... Read more









